JOINN Laboratories (Stock code: SH603127), the first member in JOINN family, is
the pioneer of pre-clinical CRO with an excellent track record in the field for more than two
decades in China. Also the first Chinese CRO passed US FDA inspection for GLP compliance and
received AAALAC International accreditation for the animal care programs. Accumulating comprehensive
safety study reports from JOINN have been accepted by CFDA, the authorities (OECD and Korea MFDS) of
other countries, and most importantly the US FDA, for supporting IND applications and commencing
clinical trials. In addition to the full spectrum of preclinical study services, including drug
screening, pharmacological efficacy studies, GLP toxicology assessment,
pharmacokinetic/pharmacodynamics studies, DMPK/bioanalysis, ophthalmic specialty and evaluation of
inhalation therapeutics, JOINN has been extending the range of services from preclinical to clinical
studies, including Phase I clinic trial (JOINN Clinic) and Pharmacovigilance (JOINN Medsafe).
Equipped with state of the art GMP facility in Bay Area, California, JOINN Biologics, a new member
of JOIN family, is committed to the advancement of biopharmaceutics through its premier contract
manufacturing and development services for biologics and advanced therapies. JOINN Bio provides a
complete range of services from early R&D stage to clinical phase manufacturing to clients,
including molecular/developability assessment, non-GMP protein expression & purification, cell line
development, upstream process development, downstream purification development, cGMP clinical trial
materials production and commercial scale cGMP manufacturing. Together with the goals of
accelerating the development of new drugs for human beings and delivering long-lasting value to the
biopharmaceutical industry, JOINNs are devoted to creating a healthier world.
